Prognosis
Gilead Covid-19 Drug May Exceed $2 Billion Sales, Piper Says
- ICER estimates remdesivir could be priced as high as $4,500
- Consumer advocacy group says drug should be sold for $1/day
Remdesivir
Photographer: Ulrich Perrey/AFP via Getty ImagesThis article is for subscribers only.
At $4,500 for a round of treatment for Covid-19, remdesivir, Gilead Sciences Inc.’s new medicine could be reasonably priced and still generate over $2 billion in revenue for the biotech, according to analysts at Piper Sandler.
That’s the maximum price that the Institute for Clinical and Economic Review recommended for a 10-day treatment of Gilead’s remdesivir, which received emergency approval from U.S. regulators on Friday. Gilead has so far been quiet on its pricing plans and didn’t immediately respond to e-mailed requests for comment.